DMAA
Drugs Made In America Acquisition Corp.
10.80$
-0.5%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | |
| – | +263,741.3% | -99.8% | +118,138.2% | -60.1% | +99.9% | +692.4% | -93.1% | -4.4% | – | |
| – | +263,741.3% | -99.8% | +118,138.2% | -60.1% | +99.9% | +692.4% | -93.1% | -4.4% | – | |
| – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | +82.4% | -4.5% | -90.3% | +825.3% | -12.4% | – | |
| – | – | – | – | +82.4% | -4.5% | -90.3% | +825.3% | -12.4% | – | |
| – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.